Clinical trials: Alzheimer's Disease(AD)
Alzheimer Disease
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.
- Trial name
- NCT05686044
- Testing
- Buntanetap/Posiphen
- Where
- 54 sites in United States
- Volunteers
- 351 people
- Sponsor
- Annovis Bio Inc.
Alzheimer Disease
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters [ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive performance and global function in patients with…
- Trial name
- Combi (NCT00911807)
- Testing
- Cerebrolysin + donepezil
- Where
- 3 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer Dementia, Alzheimer Disease
Treating Hyperexcitability in AD With Levetiracetam
The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic…
- Conditions
- Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
- Trial name
- LeAD (NCT03875638)
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer Disease, CVA (Cerebrovascular Accident)
Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA \& HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.
- Trial name
- NCT02444637
- Testing
- Rivastigmine
- Where
- Singapore
- Volunteers
- 100 people
- Sponsor
- National Neuroscience Institute
Alzheimer Disease
Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)
The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD).
- Trial name
- TEPAmy (NCT06467981)
- Testing
- Retrospective study
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Central Hospital, Nancy, France
Alzheimer's Dementia, Nursing Homes
Electronic Consultation for AD/ADRD Residents Experiencing Infectious Diseases
Pilot study to evaluate the feasibility of a pilot embedded pragmatic cluster randomized controlled trial to reduce the duration of antibiotic therapy and number of antibiotic prescriptions in nursing home residents with AD/ADRD.
- Conditions
- Alzheimer's Dementia, Nursing Homes, Antibiotics, Dementia
- Trial name
- eCARE-ID (NCT04812769)
- Testing
- eCARE-ID, Standard of Care
- Sponsor
- Yale University
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
In this study, researchers will learn more about a study drug called diranersen (BIIB080). The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
- Trial name
- CELIA (NCT05399888)
- Testing
- Diranersen
- Where
- 138 sites in United States, Australia and 15 more
- Volunteers
- 416 people
- Sponsor
- Biogen
Mild Cognitive Impairment, Alzheimer Disease
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
- Trial name
- SHARED III (NCT05584241)
- Testing
- Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan
Alzheimer's Disease (AD), Lewy Body Dementia (LBD)
Social-cognitive Functioning: Validation of a New Neuropsychological Test
It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders.
- Conditions
- Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Frontotemporal Degeneration (FTD)
- Trial name
- REALSOCOG (NCT05558709)
- Testing
- REALSOCOG, BCS, Hetero-questionnaires
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease
R21 Roche: 3-Way Tau Tracers in AD
This is an open label study to compare three new generation TAU radioligands, 18F-RO948 (formerly known as 18F-6958948), 18F-MK6240, and [18F]GTP1for imaging of taupathy and demonstrate their absence of off-target binding in…
- Trial name
- NCT05464368
- Testing
- [18F]RO-948, 18F-MK6240, 18F-GTP1
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease in Down Syndrome
Goal Attainment Scaling (GAS) Sub-Study
This is an optional sub-study that will enroll participants from LIFE-DSR parent protocol. The aim is to assess change over 16 months in individuals with Down syndrome through individualized goals set by their caregivers.
- Trial name
- NCT06484426
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- LuMind IDSC Foundation
Alzheimer's Disease
Oxaloacetate Pharmacokinetics and Safety
By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any…
- Trial name
- NCT02063308
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Russell Swerdlow, MD